Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of pharmaceuticals in South Korea. It offers general medicines, including Tiersil Once, EYE2O mini eye drops, and Optagent ophthalmic drops; medical devices; secret spotpatch quasi-drugs, and roll away products. The company also provides specialty medicines, such as Hycell solutions; Curelen, Ocufridine, Ocumetholone, Ocucyclo, Ocuhomapine, Ocucarpine, Allerfen, Optanac, Forus, Eymox, Cifex, and Ocuracin ophthalmic drops; and Herpecid, Forus, and Ocurasin ophthalmic ointments. Samil Pharmaceutical Co.,Ltd was founded in 1947 and is headquartered in Seoul, South Korea.
Research context
Samil Pharmaceutical Co.,Ltd appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Samil Pharmaceutical Co.,Ltd is currently in a long term downtrend where the price is trading 7.3% below its 200 day moving average.
From a valuation standpoint, the stock is 88.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.
Samil Pharmaceutical Co.,Ltd's total revenue sank by 0.4% to $30B since the same quarter in the previous year.
Its net income has increased by 42.4% to $-545M since the same quarter in the previous year.
Finally, its free cash flow fell by 146.9% to $-4B since the same quarter in the previous year.
Based on the above factors, Samil Pharmaceutical Co.,Ltd gets an overall score of 2/5.